Arcellx
Arcellx raises $125M Series C at $1.5B valuation
Arcellx: Series C Funding Round
Arcellx has successfully raised $125M in Series C funding, reaching a valuation of $1.5B.
Company Overview
Cell therapy company
Funding Details
The Series C round was led by Betta Pharmaceuticals, with participation from Ally Bridge Group, Frazier Healthcare Partners, EcoR1 Capital.
Company Information
- Headquarters: 9000 Virginia Manor Road, Beltsville, MD 20705
- Founded: 2014
- Employees: 200+
- Category: Biotech
Investment
Arcellx plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Betta Pharmaceuticals: Verified investor in Series C
- Ally Bridge Group: Verified investor in Series C
- Frazier Healthcare Partners: Verified investor in Series C
- EcoR1 Capital: Verified investor in Series C
Company Info
Investors (4)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free